How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Infusion Central Monitoring System Market
- By Component: Hardware, Software, Services
- By End User: Hospitals, Ambulatory Surgical Centers, Clinics, Home Healthcare Settings
- By Application: Intravenous (IV) Therapy Monitoring, Chemotherapy Infusion Monitoring, Pain Management Infusion Monitoring, Total Parenteral Nutrition (TPN) Monitoring
- By Delivery Mode: On-Premise Deployment, Cloud-Based Deployment
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Hardware leads By Component at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.158 →
- 11 Company Profiles 17 players: SWOT & benchmarking p.166 →
Full report · locked preview
Everything inside the Infusion Central Monitoring System Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Component 3
End User 4
Application 4
Delivery Mode 2
Companies profiled
Baxter International Inc.
BD (Becton
Dickinson and Company)
Smiths Medical (ICU Medical)
Fresenius Kabi
Terumo Corporation
Moog Inc.
Nihon Kohden Corporation
Mindray Medical International Limited
Philips Healthcare
GE Healthcare
Drägerwerk AG & Co. KGaA
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →BD (Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Dickinson and Company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Smiths Medical (ICU Medical)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Fresenius Kabi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Moog Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Nihon Kohden Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Mindray Medical International Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Philips Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →GE Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Drägerwerk AG & Co. KGaA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Medtronic
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Masimo Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Cerner Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Hill-Rom Holdings
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,177M by 2033 · 7.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Hardware65.8
- Software18.5
- Services15.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,179M → $2,277M · 8.6%
Europe$821.7M → $1,596M · 8.7%
Asia Pacific$750.3M → $1,390M · 8.0%
Latin America$464.4M → $804.6M · 7.1%
Middle East and Africa$357.3M → $613.2M · 7.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.032026
7.042027
7.052028
7.082029
7.092030
7.102031
7.112032
7.132033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Baxter International Inc.19.5
- BD (Becton19.2
- Dickinson and Company)8.8
- Smiths Medical (ICU Medical)7.2
- Fresenius Kabi9.8
- Terumo Corporation7.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Component22.8%
End User22.6%
Application22.2%
Delivery Mode32.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.1
- Europe23.9
- Asia Pacific20.8
- Latin America12.0
- Middle East and Africa9.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Baxter International Inc. | 80 | 97 | 91 | 98 | 84 | 76 | 88 |
| BD (Becton | 82 | 69 | 86 | 84 | 75 | 85 | 80 |
| Dickinson and Company) | 72 | 77 | 69 | 66 | 66 | 79 | 72 |
| Smiths Medical (ICU Medical) | 81 | 60 | 62 | 80 | 77 | 64 | 71 |
| Fresenius Kabi | 54 | 61 | 53 | 62 | 54 | 63 | 58 |
| Terumo Corporation | 59 | 57 | 51 | 53 | 60 | 52 | 55 |
| Moog Inc. | 45 | 62 | 50 | 59 | 49 | 42 | 51 |
| Nihon Kohden Corporation | 43 | 53 | 44 | 42 | 45 | 57 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Baxter International Inc.
- BD (Becton
- Dickinson and Company)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Baxter International Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| BD (Becton | ✓ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Dickinson and Company) | ✓ | ◐ | − | − | ✓ | ◐ |
| Smiths Medical (ICU Medical) | ✓ | ◐ | − | ◐ | ◐ | ◐ |
| Fresenius Kabi | − | − | − | − | − | ◐ |
| Terumo Corporation | ◐ | ◐ | − | − | ◐ | ◐ |
| Moog Inc. | − | ◐ | − | ◐ | ◐ | ◐ |
| Nihon Kohden Corporation | ◐ | − | ◐ | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Baxter International Inc.88
2BD (Becton80
3Dickinson and Company)72
4Smiths Medical (ICU Medical)71
5Fresenius Kabi58
6Terumo Corporation55
7Moog Inc.51
8Nihon Kohden Corporation47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Baxter International Inc.BD (Becton
Challenger2
Strong scale, closing on the leaders.
Dickinson and Company)Smiths Medical (ICU Medical)
Contender1
Focused players with pockets of strength.
Fresenius Kabi
Niche3
Specialists in a single segment or region.
Terumo CorporationMoog Inc.Nihon Kohden Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Component in North America, then scale across Infusion Central Monitoring System Market — a $337M beachhead inside a $5.03B market.
Beachhead (SOM)$337Mobtainable near-term
Serviceable (SAM)$2.05Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Hardware
Best fit — highest urgency & budget in Component.
Economic buyer79 fit
Software
Strong fit — clear ROI and a fast path to value.
End user67 fit
Services
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Component in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel32%
Digital / self-serve18%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Component leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Infusion Central Monitoring System Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified21%
Evaluation12%
Closed-won7%
$13.0KCAC
$66KLTV
5.1:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Infusion Central Monitoring System Market is a durable-growth opportunity — $8.36B by 2033, compounding at 7.2%.
TAM · 2025$4.78Btoday
TAM · 2033$8.36Bforecast
CAGR7.2%2027–2033
Cumulative$57.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.36BTotal addressable market
SAM$3.14BServiceable available market
SOM$509MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.2% CAGR
Demand compounds through 2033, outpacing GDP across Component.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Component moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.36BLarge & growingTAM by 2033 at 7.2% CAGR
$3.14BServiceable nowreachable with today’s model
$509MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.52BBear4.7% CAGR
$8.36BBase7.2% CAGR
$10.7BBull9.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Infusion Central Monitoring System Market — a $5.09B market by 2033. Plan: grow share from 10.3% to 16.8%.
Market size · 2033$5.09Btotal addressable
Market CAGR7.3%2027–2033
Target share16.8%from 10.3% today
Revenue ambition$855Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.3% | 16.8% | On track |
| Revenue | $487M | $855M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 31.5% | 40.7% | On track |
| Customer retention | 84.8% | 93.5% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Component
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Component share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $105M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Component leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Infusion Central Monitoring System Market conversation — a $3.34B market you can size, segment and defend in minutes.
Market size · 2033$3.34Btotal opportunity
Growth11.3%CAGR to 2033
Addressable buyers1,339+accounts in scope
Typical ROI5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Component
Goal Grow share in Component
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5×return on cost, year one
< 2 mopayback period
$85K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Baxter International Inc.BD (BectonDickinson and Company)Smiths Medical (ICU Medical)Fresenius KabiTerumo CorporationMoog Inc.Nihon Kohden Corporation+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Infusion Central Monitoring System Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Infusion Central Monitoring System Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Infusion Catheters Market
Market size, share, segmentation and regional forecast.
$361M market · 2025 base year
View reportBehcets Disease Market
Market size, share, segmentation and regional forecast.
$485M market · 2025 base year
View reportInfusion Bottles Pharma Aseptic Filling and Closing Machine Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBiliary Biopsy Forceps Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportBilirubinometer Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportInfusion Accessories & Consumables Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportBio-Banks Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportBioburden Testing Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBiochip Products and Services Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportBiocompatibility Testing Services Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportBio-imaging Technologies Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportBiologics Safety Testing Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.